This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CINC CinCor Pharma (CINC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About CinCor Pharma Stock (NASDAQ:CINC) 30 days 90 days 365 days Advanced Chart Get CinCor Pharma alerts:Sign Up Key Stats Today's Range$29.02▼$29.3550-Day Range$28.73▼$29.5652-Week Range$10.53▼$43.15Volume6.35 million shsAverage Volume818,447 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. Read More Receive CINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CINC Stock News HeadlinesAstraZeneca’s Phase III trial of baxdrostat shows mean SBP reductionJuly 16 at 5:05 AM | msn.comAstra Says Potential Blockbuster Reduced High Blood PressureJuly 14, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 19 at 2:00 AM | American Alternative (Ad)AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To ReactJuly 14, 2025 | msn.comAstraZeneca drug lowers high blood pressure in late-stage studyJuly 14, 2025 | msn.comFormer CinCor execs raise $3.8M for new Cincinnati biopharma firmJanuary 28, 2025 | bizjournals.comCinRx Pharma portfolio company CinDome raises $40M toward Series B roundMay 28, 2024 | bizjournals.comDelveInsight Business Research, LLP: Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | finanznachrichten.deSee More Headlines CINC Stock Analysis - Frequently Asked Questions When did CinCor Pharma IPO? CinCor Pharma (CINC) raised $176 million in an IPO on the week of November 7th 2022. The company issued 11,000,000 shares at a price of $15.00-$17.00 per share. What other stocks do shareholders of CinCor Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that CinCor Pharma investors own include ARMOUR Residential REIT (ARR), AstraZeneca (AZN), AGNC Investment (AGNC), Amgen (AMGN), Broadcom (AVGO), Costco Wholesale (COST) and Cisco Systems (CSCO). Company Calendar Today7/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CINC CIK1868734 Webwww.cincor.com Phone844-531-1834FaxN/AEmployees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)($17.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.37 million Net MarginsN/A Pretax MarginN/A Return on Equity-33.03% Return on Assets-27.21% Debt Debt-to-Equity RatioN/A Current Ratio51.96 Quick Ratio51.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.74) per share Price / Book-16.70Miscellaneous Outstanding Shares43,760,000Free Float36,937,000Market Cap$1.27 billion OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CINC) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CinCor Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CinCor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
